STOCK TITAN
  1. Home
  2. News
  3. MESO

Mesoblast Ltd - MESO STOCK NEWS

Welcome to our dedicated news page for Mesoblast (Ticker: MESO), a resource for investors and traders seeking the latest updates and insights on Mesoblast.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mesoblast's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mesoblast's position in the market.

News
Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023
Rhea-AI Summary
Mesoblast Limited provided an activity report for the first quarter ended September 30, 2023. The company had a productive meeting with the FDA regarding potential approvals of Ryoncil® in steroid-refractory acute graft versus host disease (SR-aGVHD). Mesoblast presented clinical data indicating high survival rates in children with SR-aGVHD using the improved RYONCIL product version. They believe these studies will support approval for the pediatric indication. Mesoblast also plans to commence a Phase 3 trial of RYONCIL in adults and adolescents with refractory aGVHD. The company has implemented cost reduction strategies and payroll reductions to preserve cash and reduce spend by 23% year on year. Cash balance at the end of the quarter was $53.2 million, with net operating cash spend of $14.2 million. Revenue from royalties on sales in Japan grew by 24% compared to the previous year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
none
-
News
Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee
Rhea-AI Summary
Mesoblast Limited appoints Jane Bell AM as Chair of the Board Audit and Risk Committee. She will focus on cost containment and cash preservation initiatives, targeting a 23% reduction ($15 million) in annual net operating cash for FY2024 and a 40% reduction in payroll by February 2024. She will also work on strengthening the balance sheet through royalty monetization and strategic partnerships.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
none
-
News
Key Outcomes From FDA Type A Meeting and Mesoblast Next Steps to Achieve RYONCIL Approval
Rhea-AI Summary
Mesoblast provides update on approval path for remestemcel-L in the treatment of SR-aGVHD
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.82%
Tags
none
News
Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023
Rhea-AI Summary
Mesoblast reports financial results and operational update for Q2 2023, outlines cost containment strategy and discusses progress on remestemcel-L and rexlemestrocel-L
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.59%
Tags
earnings
-
News
Mesoblast Financial Results and Corporate Update Webcast
Rhea-AI Summary
Mesoblast to host webcast discussing Q4 and full year 2023 results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.27%
Tags
earnings
-
News
Mesoblast Receives Complete Response From U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children
Rhea-AI Summary
Mesoblast Limited announced that the FDA has provided a complete response to its Biologics License Application for remestemcel-L for the treatment of pediatric steroid-refractory acute graft versus host disease. More data is required for marketing approval, and Mesoblast will conduct a targeted study in adults. The company remains committed to making remestemcel-L available to patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-58.9%
Tags
none
News
Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2023
Rhea-AI Summary
Mesoblast Limited (Nasdaq:MESO; ASX:MSB) reported a cash balance of US$71.3 million at the end of the fourth quarter, with an additional US$40 million available. Revenue from royalties on sales of TEMCELL® HS Inj.1 in Japan was US$2.0 million. Net cash usage for operating activities was US$16.3 million, with US$7.2 million for manufacturing activities. The Biologics License Application (BLA) resubmission for remestemcel-L was accepted by the FDA with a goal date of August 2, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Coya Therapeutics (“Coya”) Appoints Industry and Drug Development Veteran, Dr. Fred Grossman, to President and Chief Medical Officer succeeding Dr. Adrian Hepner
Rhea-AI Summary
Coya Therapeutics appoints Dr. Fred Grossman as President and Chief Medical Officer, succeeding Dr. Adrian Hepner. Dr. Grossman brings over 20 years of drug development expertise and will guide Coya's development programs, including COYA 302 for ALS treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
management
-
News
Mesoblast Director Philip R. Krause, M.D., Appointed to Strategic Advisory Role
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
none
News
Mesoblast Reports Operational and Financial Highlights for Quarter Ended March 31, 2023
Rhea-AI Summary
Mesoblast Limited reported operational highlights and financial results for the period ended March 31, 2023. The FDA accepted the company's filing for the Biologics License Application (BLA) for remestemcel-L in the treatment of children with steroid-refractory graft versus host disease (SR-aGVHD) and set a goal date of August 2, 2023. The FDA also conducted a pre-license inspection of the manufacturing process for remestemcel-L. Mesoblast received Regenerative Medicine Advanced Therapy (RMAT) designation for rexlemestrocel-L in the treatment of chronic low back pain (CLBP) and expects enrollment for the pivotal trial to begin in Q3 2023. The DREAM-HF Phase 3 trial results for rexlemestrocel-L in patients with chronic heart failure were published in the Journal of the American College of Cardiology (JACC).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.22%
Tags
none
Stock MESO logo
Mesoblast Ltd

Nasdaq:MESO

MESO Rankings

#2808 Ranked by Market Cap
#4906 Ranked by Stock Gains
N/A Ranked by Dividends

MESO Stock Data

570.76M
796.57M
0.75%
2.31%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Australia
Melbourne

About MESO

mesoblast; (asx: msb; nasdaq:meso) is a world leader in innovative cell-based medicines. we have leveraged our proprietary technology platforms based on specialized cells known as mesenchymal lineage adult stem cells (mlcs) to establish what we believe is the most advanced cellular medicines portfolio in the industry. our ‘off-the-shelf’ products are allogeneic - meaning cells from one donor may be used in many different recipients without the need for matching. our licensee in japan has launched its mlc-based product for acute graft versus host disease in children and adults in japan. it is the first allogeneic cell-based product in japan to be fully approved in japan. we believe we are well positioned to have the first industrially manufactured allogeneic cell-based product approved in the united states. our lead product candidates under investigation are: • mpc-150-im for chronic heart failure • mpc-06-id for chronic low back pain due to disc degeneration • msc-100-iv for acute graf